Nxera Pharma Co., Ltd. SOLTF
8.50 USD 0.00 (+0.00%)
At close·Nov 2, 2026, 4:00 PM EST
- YTD
- +55.11%
- 1 year
- +38.44%
Altman Z-Score
1.58 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
5 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
P/E -6.2×
P/S 2.6×
P/B 1.3×
P/FCF -24.9×
EV/EBITDA -30.9×
EV/Sales 3.9×
FCF Yield -4.0%
Gross Margin 60.7%
Operating Margin -27.3%
Net Margin -42.3%
ROE -20.5%
ROIC -5.5%
ROA -9.3%
Revenue 2.8%
Operating Income -49.1%
EPS (diluted) -157.3%
Free Cash Flow 66.3%
Current Ratio 2.5×
Quick Ratio 1.9×
Debt / Equity 0.9×
Net Debt / EBITDA -10.0×
Interest Coverage -1.1×
Dividend Yield 0.0%
Payout Ratio 0.0%
Annual · latest fiscal year ends 2025-12-31